Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This analysis evaluated patient-related outcomes between those who did and did not receive consolidation durvalumab after chemoradiotherapy for unresectable stage III non–small cell lung cancer.
Definitive treatment to the primary site improves overall and cancer-specific survival among patients with brain-only NSCLC metastases, a recent retrospective study shows.
Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.
The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2 non–small cell lung cancer.
A new study reveals that baseline EGFR mutations may be key to making the decision in the frontline setting.